Free weekly newsletter
Get the free weekly contract digest
The new new contracts, who’s behind them, and what they mean — delivered to your inbox every week. No credit card, unsubscribe anytime.
Weekly Digest
New new contracts, summarized for you
Straight to Inbox
No login, no app to check — it comes to you
Contract Trends
See who's moving and how much in your market
No credit card required Weekly contract digest
Revolution Medicines partners with Royalty Pharma for $2 billion funding to enhance oncology therapies.
Jun 24, 2025•12 months ago
Contract Type
partnership
Redwood CityBiotechnologyHealthcareHealth CareTherapeuticsPharmaceuticalDescription
Revolution Medicines has entered into a partnership with Royalty Pharma to secure $2 billion in financing. This funding will empower Revolution to independently develop and commercialize its RAS(ON) inhibitors while retaining full control over its strategic direction.
Agreement Insights
Based on industry dataStrategic partnership established
Partnership agreements typically involve technology integration and joint go-to-market strategies
Contract momentum indicator
Companies with recent agreements are 2.3x more likely to make additional purchases within 6 months